Roche bid for Genentech faces lawsuit Roches $43.7 billion (21.8 billion) takeover of the 41 per cent of Genentech it does not already own was yesterday met with a lawsuit claiming that the deal short-changed shareholders.Switzerlands Roche announced on Monday that it had...
SWCRF Researcher Identifies Ways to Significantly Expand the Applicability of a Unique Anti-Cancer Drug Wilson H.Miller, Jr.
Millers research has identified how arsenic trioxide can be used in combination with other cancer-fighting drugs to significantly increase the overall anti-cancer effect.
Arsenic trioxide-based combination therapy...
SWCRF Researcher Identifies Ways to Significantly Expand the Applicability of a Unique Anti-Cancer Drug Wilson H.Miller, Jr.
Professor Department of Medicine Division of Experimental Medicine McGill University NEW YORK, July 22, 2008--Arsenic Trioxide is a drug with an amazing impact on reversing the growth of acute promyelocytic leukemia...
Roche looks to maximize Genentech potential Roche has initiated efforts to acquire all outstanding shares in Genentech for approximately $43.7 billion, having purchased 55.9% of the company in 1990.While Genentech has historically operated independently from its parent company, it...
Genentech shareholders sue over Roche bid The suit, brought in Delaware Chancery Court, seeks to block the Swiss drugmaker's bid from going forward under its current terms.Roche has offered to buy all outstanding shares in Genentech, its U.S.
partner, for $89 a share in cash to...
Genentech shareholders sue over Roche bid NEW YORK (Reuters) - A Genentech Inc investor filed a lawsuit on Wednesday over the proposed $43.7 billion buyout by majority shareholder Roche Holding AG , saying the bid is unfair and inadequate.The suit, brought in Delaware Chancery...
Roche bids for remaining Genentech stake The Swiss pharmaceutical giant Roche has offered nearly US$44 billion to acquire the 44% of biotechnology jewel Genentech that it doesn't already own.The offer immediately raised questions about how independent the highly successful,...
What Now, Genentech Investors? AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles 1 Member Recommended this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.Adam will be speaking to...
MOST READ: What Now, Genentech Investors? AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles 1 Member Recommended this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.Adam will be speaking to...
What Now, Genentech Investors? AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles Be the First Member to Recommend this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.Adam will be...
[external] What Now, Genentech Investors? AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles Be the First Member to Recommend this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.Adam will be...
Roche $43.7B Genentech Offer Likely to Feel Upward Pressure Byline: Donna Young, Washington Editor Roche Holding AG has offered $43.7 billion, or $89 per share, to buy the 44 percent it does not own already of Genentech Inc., the world's largest biotech.If the merger is completed, Basel,...
What Now, Genentech Investors? AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles Be the First Member to Recommend this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.Adam will be...
What Now, Genentech Investors? When Roche eventually completes the job of DNA Where will all that money go?The most obvious answer is right back into the other large-cap biotech firms like Celgene CELG A Mini-Genentech Spinoff?
Yes, it's probably too early to think...
Roche-Genentech deal could spark worker defections LOS ANGELES, July 22 (Reuters) - Roche Holding AG (News/Aktienkurs) 's <ROG.VX> plan to buy Genentech Inc (News) <DNA.N> runs the risk of triggering an exodus of employees who do not want to work for a huge company, including...
Roche-Genentech deal could spark worker defections LOS ANGELES, July 22 (Reuters) - Roche Holding AG's <ROG.VX> plan to buy Genentech Inc <DNA.N> runs the risk of triggering an exodus of employees who do not want to work for a huge company, including some who might look...
Genentech mulls offer by Roche; stocks rise SAN FRANCISCO - Biotechnology pioneer Genentech Inc.mulled Roche Holding's $43.7 billion offer for its remaining shares Monday as investors made clear their feelings that the Swiss pharmaceutical giant should pay considerably more.
But...
Roche-Genentech deal could spark worker defections LOS ANGELES, July 22 (Reuters) - Roche Holding AG's (ROG.VX: Quote, Profile, Research) plan to buy Genentech Inc (DNA.N: Quote, Profile, Research) runs the risk of triggering an exodus of employees who do not want to work for a huge company,...
Roche Posts Very Good Results: Strong Market Outperformance Guidance Confirmed Group sales increase 10% in local currencies (excluding Tamiflu pandemic sales) to 22 billion Swiss francs(+1% in Swiss francs; +18% in US dollars).Including Tamiflu pandemic sales, Group sales rise 4% in local currencies (-4% in Swiss...
Roche-Genentech: A Drug Powerhouse Just months into his new role as chief executive of Roche Holding (RHHBY), Severin Schwann is moving quickly to cement one of the most successful biotech pharmaceutical partnerships in history.Eighteen years after taking a majority stake...
Roche-Genentech deal could spark worker defections LOS ANGELES -- Roche Holding AG's plan to buy Genentech Inc runs the risk of triggering an exodus of employees who do not want to work for a huge company, including some who might look to start their own companies, industry sources have said...
Roche-Genentech deal could spark worker defections LOS ANGELES (Reuters) - Roche Holding (other-otc: RHHBY.PK - news - people ) AG's plan to buy Genentech Inc (nyse: DNA - news - people ) runs the risk of triggering an exodus of employees who do not want to work for a huge company, including...
Roche likely to raise bid for Genentech: analysts LOS ANGELES (Reuters) - Roche Holding AG may need to raise its $43.7 billion bid for the Genentech Inc stock that it does not already own, but an eventual deal is likely, analysts and investors said on Monday.The Swiss drug maker already...
Genentech shares surge on Roche's $44 billion offer Wall Street analysts say the bid will have to go to $95 to $100 to get a deal done.'It will get done but at a higher price,' says Christopher Raymond, Genentech analyst at Robert W.
Baird.
Lazard Capital Markets analyst Joel Sendek...
Genentech shares soar on Roche bid prospects Shares of biotech leader Genentech soared 15 percent Monday on expectations that drugmaker Roche will have to raise its bid of $89 a share for the 44 percent of Genentech it doesn't already own.Roche's $43.7 billion all-cash offer, issued...
